Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Venetoclax in R/R Pediatric ALL/LBL (HEM-iSMART C)
NCT05745714Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2025
- Primary completion
- Feb 2032
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib and venetoclax in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 3 years and Best Overall Response Rate at 6 years. Started Oct 2025; status: recruiting.
02
Drugs
ruxolitinibvenetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT05745714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745714.